Delrieu I. auteur aut IRD Leboulleux D. auteur aut IRD Ivinson K. auteur aut IRD Gessner B. D. auteur aut IRD Chandramohan D. auteur aut IRD Churcher T. auteur aut IRD Drakeley C. auteur aut IRD Halloran E. auteur aut IRD Killeen G. auteur aut IRD Kleinschmidt I. auteur aut IRD Milligan P. auteur aut IRD Robert Vincent auteur aut IRD Rogier C. auteur aut IRD Saul A. auteur aut IRD Sinden R. auteur aut IRD Smith T. auteur aut IRD text journalArticle eng text/pdf born digital access Vaccines interrupting Plasmodium falciparum malaria transmission targeting sexual, sporogonic, or mosquito-stage antigens (SSM-VIMT) are currently under development to reduce malaria transmission. An international group of malaria experts was established to evaluate the feasibility and optimal design of a Phase III cluster randomized trial (CRT) that could support regulatory review and approval of an SSM-VIMT. The consensus design is a CRT with a sentinel population randomly selected from defined inner and buffer zones in each cluster, a cluster size sufficient to assess true vaccine efficacy in the inner zone, and inclusion of ongoing assessment of vaccine impact stratified by distance of residence from the cluster edge. Trials should be conducted first in areas of moderate transmission, where SSM-VIMT impact should be greatest. Sample size estimates suggest that such a trial is feasible, and within the range of previously supported trials of malaria interventions, although substantial issues to implementation exist. specialized Transmission blocking vaccine Malaria Trial design Cluster randomized trial AFRIQUE SUBSAHARIENNE ZONE TROPICALE 052 050 33 13 1518-1526 2015 0264-410X https://www.documentation.ird.fr/hor/fdi:010064145 10.1016/j.vaccine.2015.01.050 0264-410X [F B010064145] https://www.documentation.ird.fr/hor/fdi:010064145 https://www.documentation.ird.fr/intranet/publi/2015/05/010064145.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2015-06-04 2017-08-23 fdi:010064145 fre